News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG to Participate in Raymond James Life Sciences and MedTech Conference in June

PDF Berlin (Germany) and San Diego, CA (U.S.A.), June 4, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced that company management will be presenting at the Raymond James Life Sciences and MedTech Conference in New York on Tuesday, June 18, 2019, at 1:50 pm (EDT) / 7:50 pm (CET) and invites […]

Read more

New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon® Blood Test

PDF Data Presented at DDW 2019 Show 93.6% Acceptance Rate Among Patients Unwilling or Unable to Complete Other CRC Screening Tests Berlin (Germany) and San Diego, CA (U.S.A.), May 20, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation […]

Read more

Epi proColon® Receives the 2019 Excellence in Molecular Diagnostics Award

PDF Corporate LiveWire acknowledges the importance of a patient-accepted CRC detection method to effectively diagnose colorectal cancer. Berlin (Germany) and San Diego, CA (U.S.A.), May 9, 2019 –  Epigenomics AG is honored to have Epi proColon® recognized as the 2019 Excellence in Molecular Diagnostics award by Corporate LiveWire as part of the Innovation and Excellence […]

Read more

Epigenomics AG Reports 2019 First Quarter Financial Results

PDF Berlin (Germany) und San Diego, CA (U.S.A.), May 8, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced the financial results (according to IFRS; unaudited) for the first quarter of the FY 2019. KEY HIGHLIGHTS Financial Total revenue increased to EUR 331 thousand (Q1 2018: EUR 309 thousand) primarily due to […]

Read more

CMS accepts Epigenomics’ application for NCD review

PDF Berlin (Germany) and San Diego, CA (U.S.A.), May 3, 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that the Centers for Medicare & Medicaid Services (CMS) has accepted the company’s application for a National Coverage Determination (NCD) review of Epi proColon, Epigenomics’ blood test for colorectal cancer screening. The […]

Read more

Epigenomics AG Reports Results for Financial Year 2018

PDF Berlin (Germany) und San Diego, CA (U.S.A.), March 27, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced the financial results (according to IFRS) for the year ended December 31, 2018. KEY HIGHLIGHTS Financial – Total revenue of EUR 1.5 million and EBITDA (before share-based payment expenses) of EUR -11.4 million (compared […]

Read more